Literature DB >> 19808994

Safe treatment of pulmonary hypertension with bosentan in a patient with moyamoya disease and cerebral ischemia.

Ronald W Day1, Douglas L Brockmeyer, G Peter Feola.   

Abstract

A 7-year-old girl with Down syndrome and moderately severe pulmonary hypertension experienced a stroke while being treated with a calcium channel blocker. Angiography identified bilateral stenosis of the supraclinoid internal carotid arteries, stenosis or occlusion of the proximal anterior and middle cerebral arteries, and occlusion of the left posterior cerebral artery. She underwent surgery to enhance collateral blood flow to vulnerable areas of the brain. Her pulmonary hypertension therapy was changed to an oral endothelin receptor antagonist. She developed excellent collateral blood flow through external carotid arteries to each cerebral hemisphere and an improvement in blood flow through the right internal carotid artery. This case suggests that bosentan can be used safely in children with moyamoya disease. Additional studies are needed to determine whether endothelin receptor antagonists may influence the progression of moyamoya disease or the development of collateral cerebral blood flow following surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808994     DOI: 10.1177/0883073809339360

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Electrophysiological effects of bosentan in rats with induced cerebral ischemia-reperfusion.

Authors:  Bekir Akgun; Metin Kaplan; Caner F Demir; Aysel Sarı; Hasan H Ozdemir; Said M Berilgen
Journal:  Bosn J Basic Med Sci       Date:  2013-08       Impact factor: 3.363

2.  Ameliorative Effect of a Selective Endothelin ETA Receptor Antagonist in Rat Model of L-Methionine-induced Vascular Dementia.

Authors:  Gautamjeet S Mangat; Amteshwar S Jaggi; Nirmal Singh
Journal:  Korean J Physiol Pharmacol       Date:  2014-06-12       Impact factor: 2.016

3.  Atypical presentation of moyamoya disease with pulmonary hypertension: A case report.

Authors:  Mete Han Kızılkaya; Fahrettin Uysal; Emre Gürbüz; Mevlüt Özgür Taşkapılıoğlu; Özlem Mehtap Bostan
Journal:  Anatol J Cardiol       Date:  2018-05       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.